Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Progress and prospects: graft-versus-host disease

Gene Therapy volume 17, pages 1309–1317 (2010)Cite this article

Subjects

Abstract

Graft-versus-host disease (GvHD) is one of the major complications of allogeneic hematopoietic stem cell transplantation, an otherwise highly effective therapeutic modality for patients affected by hematological diseases. The main inducers of GvHD are alloreactive donor T cells, which recognize host antigens presented by recipient cells. The critical role of lymphocytes in GvHD is well documented by the observation that T-cell depletion from the graft prevents GvHD. Unfortunately, the removal of donor lymphocytes from the graft increases the incidence of disease relapse and life-threatening infectious complications. Gene transfer technologies are promising tools to manipulate donor T-cell immunity to enforce graft-versus-tumor/graft-versus-infection while preventing or controlling GvHD. For this purpose, several cell and gene transfer approaches have been investigated at the preclinical level and implemented in clinical trials.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Baker KS, Fraser CJ . Quality of life and recovery after graft-versus-host disease. Best Pract Res Clin Haematol 2008; 21: 333–341.

    Article  Google Scholar 

  2. Deeg HJ . How I treat refractory acute GVHD. Blood 2007; 109: 4119–4126.

    Article  CAS  Google Scholar 

  3. Gratwohl A, Baldomero H, Schwendener A, Rocha V, Apperley J, Frauendorfer K et al. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant 2009; 43: 275–291.

    Article  CAS  Google Scholar 

  4. Aversa F, Reisner Y, Martelli MF . The haploidentical option for high-risk haematological malignancies. Blood Cells Mol Dis 2008; 40: 8–12.

    Article  Google Scholar 

  5. Huang XJ . Current status of haploidentical stem cell transplantation for leukemia. J Hematol Oncol 2008; 1: 27.

    Article  Google Scholar 

  6. Ferrara JL, Levine JE, Reddy P, Holler E . Graft-versus-host disease. Lancet 2009; 2: 1550–1561.

    Article  Google Scholar 

  7. Dickinson AM, Holler E . Polymorphisms of cytokine and innate immunity genes and GVHD. Best Pract Res Clin Haematol 2008; 21: 149–164.

    Article  CAS  Google Scholar 

  8. Biedermann BC . Vascular endothelium and graft-versus-host disease. Best Pract Res Clin Haematol 2008; 21: 129–138.

    Article  CAS  Google Scholar 

  9. Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008; 111: 2470–2475.

    Article  CAS  Google Scholar 

  10. Shlomchik WD . Graft-versus-host disease. Nat Rev Immunol 2007; 7: 340–352.

    Article  CAS  Google Scholar 

  11. Riddell SR, Appelbaum FR . Graft-versus-host disease: a surge of developments. PLoS Med 2007; 4: 198.

    Article  Google Scholar 

  12. Cho BS, Min CK, Eom KS, Kim YJ, Kim HJ, Lee S et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia 2009; 23: 78–84.

    Article  Google Scholar 

  13. Bacigalupo A . Management of acute graft-versus-host disease. Br J Haematol 2007; 137: 87–98.

    Article  CAS  Google Scholar 

  14. Soiffer R . Immune modulation and chronic graft-versus-host disease. Bone Marrow Transplant 2008; 42 (Suppl 1): S66–S69.

    Article  CAS  Google Scholar 

  15. Lee SJ, Flowers ME . Recognizing and managing chronic graft-versus-host disease. Hematol Am Soc Hematol Educ Program 2008; 2008: 134–141.

    Article  Google Scholar 

  16. Barrett AJ, Le Blanc K . Prophylaxis of acute GVHD: manipulate the graft or the environment? Best Pract Res Clin Haematol 2008; 21: 165–176.

    Article  CAS  Google Scholar 

  17. Alyea EP, Li S, Kim HT, Cutler C, Ho V, Soiffer RJ et al. Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 920–926.

    Article  CAS  Google Scholar 

  18. Schleuning M, Judith D, Jedlickova Z, Stübig T, Heshmat M, Baurmann H et al. Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study. Bone Marrow Transplant 2008; 43: 717–723.

    Article  Google Scholar 

  19. Besien KV, Kunavakkam R, Rondon G, De Lima M, Artz A, Oran B et al. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant 2009; 15: 610–617.

    Article  Google Scholar 

  20. Kroger N, Zabelina T, Binder T, Ayuk F, Bacher U, Amtsfeld G et al. HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen. Biol Blood Marrow Transplant 2009; 15: 454–462.

    Article  Google Scholar 

  21. Ratanatharathorn V, Logan B, Wang D, Horowitz M, Uberti JP, Ringden O et al. Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol 2009; 145: 816–824.

    Article  CAS  Google Scholar 

  22. Christopeit M, Schütte V, Theurich S, Weber T, Grothe W, Behre G . Rituximab reduces the incidence of acute graft-versus-host disease. Blood 2009; 113: 3130–3131.

    Article  CAS  Google Scholar 

  23. Berger C, Turtle CJ, Jensen MC, Riddell SR . Adoptive transfer of virus-specific and tumor-specific T cell immunity. Curr Opin Immunol 2009; 21: 224–232.

    Article  CAS  Google Scholar 

  24. Feuchtinger T, Richard C, Joachim S, Scheible MH, Schumm M, Hamprecht K et al. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. J Immunother 2008; 31: 199–206.

    Article  Google Scholar 

  25. Leen AM, Christin A, Khalil M, Weiss H, Gee AP, Brenner MK et al. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol 2008; 82: 546–554.

    Article  CAS  Google Scholar 

  26. Karlsson H, Brewin J, Kinnon C, Veys P, Amrolia PJ . Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens. J Immunother 2007; 30: 544–556.

    Article  Google Scholar 

  27. Leen AM, Christin A, Myers GD, Liu H, Cruz CR, Hanley PJ et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 2009; 114: 4283–4292.

    Article  CAS  Google Scholar 

  28. Fujita Y, Leen AM, Sun J, Nakazawa Y, Yvon E, Heslop H et al. Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother 2008; 31: 665–674.

    Article  CAS  Google Scholar 

  29. Spierings E . Minor histocompatibility antigens: targets for tumour therapy and transplant tolerance. Int J Immunogenet 2008; 35: 363–366.

    Article  CAS  Google Scholar 

  30. Wehler TC, Nonn M, Brandt B, Britten CM, Gröne M, Todorova M et al. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood 2007; 109: 365–373.

    Article  CAS  Google Scholar 

  31. Hartwig UF, Nonn M, Khan S, Link I, Huber C, Herr W . Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity. Biol Blood Marrow Transplant 2008; 14: 99–109.

    Article  CAS  Google Scholar 

  32. Mielke S, Nunes R, Rezvani K, Fellowes VS, Venne A, Solomon SR et al. A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood 2008; 111: 4392–4402.

    Article  CAS  Google Scholar 

  33. Perruccio K, Topini F, Tosti A, Carotti A, Aloisi T, Aversa F et al. Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation. Blood Cells Mol Dis 2008; 40: 76–83.

    Article  CAS  Google Scholar 

  34. Matte-Martone C, Liu J, Jain D, McNiff J, Shlomchik WD . CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL. Blood 2008; 111: 3884–3892.

    Article  CAS  Google Scholar 

  35. Dutt S, Tseng D, Ermann J, George TI, Liu YP, Davis CR et al. Naive and memory T cells induce different types of graft-versus-host disease. J Immunol 2007; 179: 6547–6554.

    Article  CAS  Google Scholar 

  36. Zheng H, Matte-Martone C, Li H, Anderson BE, Venketesan S, Sheng Tan H et al Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. Blood 2008; 111: 2476–2484.

    Article  CAS  Google Scholar 

  37. Chen BJ, Deoliveira D, Cui X, Le NT, Son J, Whitesides JF et al. Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse. Blood 2007; 109: 3115–3123.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Dodero A, Carniti C, Raganato A, Vendramin A, Farina L, Spina F et al. Haploidentical stem cell transplantation following a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: post-transplant CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood 2009; 113: 4771–4779.

    Article  CAS  Google Scholar 

  39. Toubai T, Sun Y, Reddy P . GVHD pathophysiology: is acute different from chronic? Best Pract Res Clin Haematol 2008; 21: 101–117.

    Article  CAS  Google Scholar 

  40. von Bonin M, Stölzel F, Goedecke A, Richter K, Wuschek N, Hölig K et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009; 43: 245–251.

    Article  CAS  Google Scholar 

  41. Baker M . Stem-cell drug fails crucial trials. Nature 2009; e-pub ahead of print 9 September 2009.

  42. Nguyen VH, Shashidhar S, Chang DS, Ho L, Kambham N, Bachmann M et al. The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood 2008; 111: 945–953.

    Article  CAS  Google Scholar 

  43. Edinger M, Powrie F, Chakraverty R . Regulatory mechanisms in graft-versus-host responses. Biol Blood Marrow Transplant 2008; 15: 2–6.

    Article  Google Scholar 

  44. Sun Y, Tawara I, Toubai T, Reddy P . Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res 2007; 150: 197–214.

    Article  CAS  Google Scholar 

  45. Allan SE, Broady R, Gregori S, Himmel ME, Locke N, Roncarolo MG et al. CD4+ T-regulatory cells: toward therapy for human diseases. Immunol Rev 2008; 223: 391–421.

    Article  CAS  Google Scholar 

  46. Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009; 10: 489–500.

    Article  Google Scholar 

  47. Bonini C, Bondanza A, Perna SK, Kaneko S, Traversari C, Ciceri F et al. The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther 2007; 15: 1248–1252.

    Article  CAS  Google Scholar 

  48. Ciceri F, Bonini C, Marktel S, Zappone E, Servida P, Bernardi M et al. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 2007; 109: 4698–4707.

    Article  CAS  Google Scholar 

  49. Deschamps M, Robinet E, Certoux JM, Mercier P, Sauce D, De Vos J et al. Transcriptome of retrovirally transduced CD8+ lymphocytes: influence of cell activation, transgene integration, and selection process. Mol Immunol 2008; 45: 1112–1125.

    Article  CAS  Google Scholar 

  50. Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P et al. A survey of fully-haploidentical hematopoietic stem cells transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients transplanted in remission. Blood 2008; 112: 3574–3581.

    Article  CAS  Google Scholar 

  51. Bennour E, Ferrand C, Rémy-Martin JP, Certoux JM, Gorke S, Qasim W et al. Abnormal expression of only the CD34 part of a transgenic CD34/herpes simplex virus-thymidine kinase fusion protein is associated with ganciclovir resistance. Hum Gene Ther 2008; 19: 699–709.

    Article  CAS  Google Scholar 

  52. Kaneko S, Mastaglio S, Bondanza A, Ponzoni M, Sanvito F, Aldrighetti L et al. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood 2009; 113: 1006–1015.

    Article  CAS  Google Scholar 

  53. Traversari C, Marktel S, Magnani Z, Mangia P, Russo V, Ciceri F et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood 2007; 109: 4708–4715.

    Article  CAS  Google Scholar 

  54. Mercier-Letondal P, Deschamps M, Sauce D, Certoux JM, Milpied N, Lioure B et al. Early immune response against retrovirally-transduced herpes simplex virus-thymidine kinase-expressing gene-modified T cells coinfused with a T cell-depleted marrow graft: an altered immune response? Hum Gene Ther 2008; 19: 937–950.

    Article  CAS  Google Scholar 

  55. Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK . Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 913–924.

    Article  CAS  Google Scholar 

  56. Nakazawa Y, Huye LE, Dotti G, Foster AE, Vera JF, Manuri PR et al. Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes. J Immunother 2009; 32: 826–836.

    Article  CAS  Google Scholar 

  57. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114: 535–546.

    Article  CAS  Google Scholar 

  58. Burns WR, Zheng Z, Rosenberg SA, Morgan RA . Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. Blood 2009; 114: 2888–2899.

    Article  CAS  Google Scholar 

  59. van Loenen MM, Hagedoorn RS, Kester MG, Hoogeboom M, Willemze R, Falkenburg JH et al. Kinetic preservation of dual specificity of coprogrammed minor histocompatibility antigen-reactive virus-specific T cells. Cancer Res 2009; 69: 2034–2041.

    Article  CAS  Google Scholar 

  60. Teague RM, Greenberg PD, Fowler C, Huang MZ, Tan X, Morimoto J et al. Peripheral CD8+ T cell tolerance to self-proteins is regulated proximally at the T cell receptor. Immunity 2008; 28: 662–674.

    Article  CAS  Google Scholar 

  61. Heemskerk MH, Hagedoorn RS, van der Hoorn MA, van der Veken LT, Hoogeboom M, Kester MG et al. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood 2007; 109: 235–243.

    Article  CAS  Google Scholar 

  62. Kuball J, Dossett ML, Wolfl M, Ho WY, Voss RH, Fowler C et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 2007; 109: 2331–2338.

    Article  CAS  Google Scholar 

  63. Cohen CJ, Li YF, El-Gamil M, Robbins PF, Rosenberg SA, Morgan RA et al. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res 2007; 67: 3898–3903.

    Article  CAS  Google Scholar 

  64. Hart DP, Xue SA, Thomas S, Cesco-Gaspere M, Tranter A, Willcox B et al. Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells. Gene Therapy 2008; 15: 625–631.

    Article  CAS  Google Scholar 

  65. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008; 112: 2261–2271.

    Article  CAS  Google Scholar 

  66. Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother 2009; 32: 169–180.

    Article  CAS  Google Scholar 

  67. Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res 2008; 68: 2961–2971.

    Article  CAS  Google Scholar 

  68. Leen AM, Rooney CM, Foster AE . Improving T cell therapy for cancer. Annu Rev Immunol 2007; 25: 243–265.

    Article  CAS  Google Scholar 

  69. Sadelain M, Brentjens R, Riviere I . The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009; 21: 215–223.

    Article  CAS  Google Scholar 

  70. Dotti G, Savoldo B, Brenner M . Fifteen years of gene therapy based on chimeric antigen receptors: ‘Are we nearly there yet?’. Hum Gene Ther 2009; 20: 1229–1239.

    Article  CAS  Google Scholar 

  71. Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009; 113: 6392–6402.

    Article  CAS  Google Scholar 

  72. Kolb HJ . Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008; 112: 4371–4383.

    Article  CAS  Google Scholar 

  73. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26: 5233–5239.

    Article  CAS  Google Scholar 

  74. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008; 358: 2698–2703.

    Article  CAS  Google Scholar 

  75. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008; 118: 294–305.

    Article  CAS  Google Scholar 

  76. Quintarelli C, Vera JF, Savoldo B, Giordano Attianese GM, Pule M, Foster AE et al. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 2007; 110: 2793–2802.

    Article  CAS  Google Scholar 

  77. Vera JF, Hoyos V, Savoldo B, Quintarelli C, Giordano Attianese GM, Leen AM et al. Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther 2009; 17: 880–888.

    Article  CAS  Google Scholar 

  78. Qasim W, Mackey T, Sinclair J, Chatziandreou I, Kinnon C, Thrasher AJ et al. Lentiviral vectors for T-cell suicide gene therapy: preservation of T-cell effector function after cytokine-mediated transduction. Mol Ther 2007; 15: 355–360.

    Article  CAS  Google Scholar 

  79. Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee YL, Kim KA et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 2007; 25: 1298–1306.

    Article  CAS  Google Scholar 

  80. Perez EE, Wang J, Miller JC, Jouvenot Y, Kim KA, Liu O et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 2008; 26: 808–816.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Hematology and BMT Unit, San Raffaele Scientific Institute, Milano, Italy

    S Mastaglio, M T L Stanghellini, A Bondanza, F Ciceri & C Bonini

  2. Division of Regenerative Medicine, Experimental Hematology Unit Cancer Immunotherapy and Gene Therapy Program, Stem Cell and Gene Therapy, San Raffaele Scientific Institute, Milano, Italy

    S Mastaglio, M T L Stanghellini, A Bondanza, F Ciceri & C Bonini

  3. University Vita-Salute, Milano, Italy

    S Mastaglio, C Bordignon, F Ciceri & C Bonini

  4. MolMed SpA, Milano, Italy

    S Mastaglio & C Bordignon

Authors
  1. S Mastaglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M T L Stanghellini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Bordignon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Bondanza
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Ciceri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Bonini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Bonini.

Ethics declarations

Competing interests

The authors declare no conflict of interest

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mastaglio, S., Stanghellini, M., Bordignon, C. et al. Progress and prospects: graft-versus-host disease. Gene Ther 17, 1309–1317 (2010). https://doi.org/10.1038/gt.2010.83

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/gt.2010.83

Keywords

This article is cited by

Search

Advanced search

Quick links